Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surrogate end points in heart failure.

Craig R Lee1, Kirkwood F Adams, J Herbert Patterson

  • 1School of Pharmacy, Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599-7360, USA.

The Annals of Pharmacotherapy
|March 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.

Clinical pharmacology and therapeutics·2026
Same author

2025 Acute Coronary Syndrome Guideline: Missing the Boat on <i>CYP2C19</i> Genotyping.

Journal of the American Heart Association·2026
Same author

Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor Therapy.

JACC. Advances·2026
Same author

Estrogen associations with human pregnancy related increases in cytochrome P450 3A activity.

Frontiers in pharmacology·2025
Same author

Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial.

Nature medicine·2025
Same author

Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants.

Clinical pharmacology and therapeutics·2025
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

Left-ventricular end-diastolic volume (LVEDV) and b-type natriuretic peptide (BNP) show promise as heart failure surrogate markers. Further research is needed to validate their use in clinical practice and drug development.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Biomarkers

Background:

  • Heart failure (HF) lacks validated surrogate markers for drug development and clinical practice.
  • Traditional markers like ejection fraction have shown inconsistent mortality prediction.
  • Understanding HF pathophysiology is crucial for identifying reliable surrogate endpoints.

Purpose of the Study:

  • Evaluate the utility of true surrogate markers for heart failure outcomes.
  • Assess the validity of commonly used surrogate markers in HF.
  • Identify potential future surrogate endpoints for HF research.

Main Methods:

  • Conducted a MEDLINE search (1966-2001) for relevant literature on HF surrogate endpoints.
  • Included additional references from selected articles.

Related Experiment Videos

  • Utilized search terms such as b-type natriuretic peptide, cardiac remodeling, and surrogate endpoints.

    • Main Results:

    • True surrogate endpoints must predict disease progression and therapeutic response.
    • Left-ventricular end-diastolic volume (LVEDV) and b-type natriuretic peptide (BNP) show potential as reliable predictors.
    • These markers correlate with disease progression and mortality reductions seen with ACE inhibitors and beta-blockers.

    Conclusions:

    • Left-ventricular end-diastolic volume (LVEDV) and plasma BNP are the most promising surrogate endpoints currently.
    • Further investigation is necessary before routine implementation in HF drug development and clinical practice.